Testosterone Cypionate vs Enclomiphene Citrate: Long-Term Durability of Response

What Each Drug Actually Does to Your Testosterone Level

Testosterone cypionate is an esterified form of testosterone injected intramuscularly. After injection, ester hydrolysis releases free testosterone over approximately 7 to 14 days, producing a predictable pharmacokinetic curve: a peak at 24 to 72 hours and a trough before the next dose. FDA labeling notes that a 200 mg dose typically produces a peak serum testosterone near 1,100 ng/dL and a trough that may fall below 400 ng/dL before the next weekly injection in some men.

Enclomiphene citrate works upstream. It blocks estrogen receptors at the hypothalamus, reducing negative feedback. The pituitary then releases more LH and FSH, which signals the testes to produce testosterone and maintain spermatogenesis. The result is higher endogenous testosterone without exogenous hormone.

The Durability Question in Plain Terms

"Durability" in this context means: how reliably does the drug maintain testosterone in the eugonadal range (300 to 1,000 ng/dL per the Endocrine Society 2018 guidelines) over months to years, and what happens when the drug is stopped or the dose is changed?

Cypionate durability is essentially pharmacological. As long as injections continue at the prescribed interval, serum testosterone remains in the therapeutic window for most men. Durability is limited only by injection adherence, site complications, or formulary changes.

Enclomiphene durability depends on biological variables: pituitary reserve, testicular Leydig cell function, and age-related changes in the HPG axis. Men with intact pituitary-gonadal axes generally respond for years. Men whose hypogonadism has a primary (testicular) component respond poorly or not at all.

Peak and Trough Variability

A 2016 analysis of the T-Trials (N=790 men aged 65 and older) published in the New England Journal of Medicine showed that testosterone gel titrated to achieve levels of 500 to 900 ng/dL produced consistent symptom improvement over 12 months. Injectable cypionate produces wider peak-to-trough swings than daily topical formulations, which some men experience as energy or mood cycling. Weekly 100 mg injections narrow this swing compared with biweekly 200 mg injections.

Long-Term Clinical Evidence for Testosterone Cypionate

What Multi-Year Data Show

The longest controlled evidence for testosterone therapy in men comes from the T-Trials program, which enrolled 790 men with low testosterone (average baseline 234 ng/dL) across seven sub-studies. Snyder et al. (NEJM, 2016) reported statistically significant improvements in sexual function, mood, and bone mineral density at 12 months, with testosterone levels maintained at a mean of approximately 600 ng/dL throughout. Observational extensions in European cohorts have followed men on injectable testosterone for up to 10 years, with consistent maintenance of total testosterone in the 400 to 700 ng/dL range when dosing is stable.

Axis Suppression: The Durability Trade-Off

Exogenous testosterone suppresses LH and FSH within days of initiation. Spermatogenesis declines sharply, reaching oligospermia or azoospermia in the majority of men within 3 to 6 months. The Endocrine Society's 2018 Clinical Practice Guideline on Male Hypogonadism explicitly states: "We recommend against testosterone therapy in male patients who desire fertility in the near term." Axis suppression is the primary durability liability of cypionate: if the drug is discontinued, the HPG axis may take 3 to 18 months to recover, and some men experience prolonged secondary hypogonadism post-cessation.

Hematocrit and Cardiovascular Monitoring

Long-term cypionate use raises hematocrit. In the T-Trials, the incidence of hematocrit exceeding 54% was 5.9% in the testosterone arm versus 0.8% in placebo. Finkle et al. (PLOS ONE, 2014) observed an elevated risk of non-fatal myocardial infarction in the 90 days following testosterone prescription initiation in older men, though more recent meta-analyses have not confirmed a durable cardiovascular harm signal in younger hypogonadal men receiving physiological replacement.

Long-Term Clinical Evidence for Enclomiphene Citrate

Phase II and III Trial Data

Enclomiphene citrate has the most rigorous trial data of any SERM studied specifically for male hypogonadism. Kim et al. (BJU International, 2016) conducted a 12-week randomized controlled trial comparing enclomiphene 12.5 mg and 25 mg daily against testosterone gel 1.62% in secondary hypogonadal men with baseline testosterone below 300 ng/dL. Key results:

• Enclomiphene 12.5 mg raised mean total testosterone from 205 ng/dL to 413 ng/dL at 12 weeks.
• Enclomiphene 25 mg raised mean total testosterone from 205 ng/dL to 489 ng/dL.
• Testosterone gel raised testosterone from 222 ng/dL to 500 ng/dL.
• Sperm concentration fell by 25% in the gel arm but rose by 8.9% in the 25 mg enclomiphene arm (P<0.05 for the between-group difference).

The trial demonstrated non-inferior testosterone recovery with preserved reproductive capacity.

Durability Beyond 12 Weeks

The central durability question for enclomiphene is what happens after year one. A subset of men in open-label extensions of the Repros Therapeutics program remained on 25 mg daily for up to 24 months and maintained testosterone levels above 300 ng/dL throughout. The response was stable as long as the drug was taken. However, testosterone returned to baseline within 2 to 4 weeks of stopping, which differs sharply from the months-long axis suppression seen after cypionate discontinuation.

Who Does Not Respond to Enclomiphene

Men with primary hypogonadism (elevated baseline LH and FSH, damaged testes from prior chemotherapy, Klinefelter syndrome, or orchitis) will not respond adequately to enclomiphene because the problem is testicular, not central. These men require exogenous androgen replacement. A baseline LH above 9.4 IU/L combined with low testosterone effectively predicts enclomiphene non-response and should direct the clinician toward cypionate or another exogenous androgen.

Head-to-Head: Durability Across Five Clinical Dimensions

The table below organizes the key durability dimensions that clinicians and patients should evaluate when choosing between these two agents.

| Dimension | Testosterone Cypionate | Enclomiphene Citrate | |---|---|---| | Testosterone maintenance (steady-state) | Predictable; driven by injection schedule | Variable; depends on HPG axis integrity | | Duration of effect after stopping | Axis recovery: 3 to 18 months | Testosterone returns to baseline in 2 to 4 weeks | | Fertility preservation | Not preserved (spermatogenesis suppressed) | Preserved; sperm concentration may improve | | LH/FSH | Suppressed to near-zero | Elevated (mechanism of action) | | Testicular volume | Decreases over time | Maintained or slightly increased | | Hematocrit risk | Elevated (monitor at 3 and 6 months) | Minimal | | Estradiol | May rise (aromatization); monitor | Rises modestly; receptor blocked centrally | | Route | Intramuscular injection (or subcutaneous) | Oral daily tablet | | Candidacy | Primary or secondary hypogonadism | Secondary hypogonadism only | | Off-label status (US) | FDA-approved for hypogonadism | Currently off-label for male hypogonadism in US |

Switching from Testosterone Cypionate to Enclomiphene Citrate

When the Switch Makes Sense

The most common clinical scenario for switching is a man on long-term TRT who now wants to attempt conception. Because cypionate has suppressed LH and FSH for months or years, the switch is not immediate. The HPG axis must recover before enclomiphene can work.

The typical recovery timeline after stopping cypionate:

1. LH and FSH begin to rise within 4 to 8 weeks in most men.
2. Spermatogenesis resumes over 3 to 6 months (longer after multi-year suppression).
3. Testosterone produced endogenously may not reach the prior TRT levels during this window, producing symptomatic hypogonadism.

Some clinicians bridge this recovery period with human chorionic gonadotropin (hCG) 1,500 to 3,000 IU three times weekly, which directly stimulates Leydig cells and maintains testosterone and testicular volume while LH receptor sensitivity is restored. Once LH rises above 2 IU/L spontaneously, enclomiphene may be initiated.

What to Expect After the Switch

Men who switch successfully and have intact Leydig cell reserve typically reach testosterone levels of 350 to 500 ng/dL on enclomiphene 25 mg daily. This is lower than the 600 to 800 ng/dL commonly achieved with weekly 100 mg cypionate injections. Men should be counseled that symptom recurrence during the transition is probable and that testosterone measurements should be checked at 6 and 12 weeks after starting enclomiphene.

The Endocrine Society guideline notes: "Clomiphene citrate and anastrozole have been used off label to treat male hypogonadism due to secondary causes, but evidence for long-term efficacy and safety is insufficient to recommend their routine use." This reflects the limited duration of published trials rather than evidence of harm, and many reproductive endocrinologists use enclomiphene routinely for this indication.

Switching from Enclomiphene to Cypionate

This direction is simpler. Enclomiphene can be stopped without concern for prolonged axis suppression. Cypionate injections may begin immediately. Because enclomiphene elevates LH and FSH, stopping it simply removes the central stimulus, and testosterone falls back to the pretreatment baseline within 2 to 4 weeks. No bridging is required.

Safety Profiles Over Time

Testosterone Cypionate Safety

Long-term cypionate use requires monitoring of hematocrit, prostate-specific antigen (PSA), and lipid panels. The T-Trials found that PSA rose by a mean of 0.31 ng/mL at 12 months in the testosterone group versus 0.07 ng/mL in placebo. No statistically significant increase in prostate cancer incidence was observed over 12 months, though the study was not powered for this endpoint.

Polycythemia (hematocrit above 52%) develops in approximately 5 to 7% of men on long-term injectable testosterone. The FDA-approved labeling for testosterone cypionate requires periodic hematocrit monitoring and dose reduction or phlebotomy if hematocrit exceeds 54%.

Cardiovascular data remain actively debated. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that testosterone therapy in men with hypogonadism and elevated cardiovascular risk did not significantly increase major adverse cardiovascular events compared with placebo (hazard ratio 1.07, 95% CI 0.94 to 1.21), though the atrial fibrillation rate was modestly elevated in the testosterone arm (3.5% vs 2.4%).

Enclomiphene Citrate Safety

The safety profile of enclomiphene at 12.5 to 25 mg daily is generally favorable. Visual disturbances, a known risk of clomiphene (the racemic parent compound), appear less common with enclomiphene because the zuclomiphene enantiomer that accumulates in ocular tissue with clomiphene is absent. No serious hepatotoxicity signals have emerged in the trial database. Estradiol rises modestly, typically remaining within normal male range at 25 mg daily. Gynecomastia has been reported in a small percentage of men in open-label use, likely when estradiol climbs above 42 pg/mL.

Because enclomiphene acts via the HPG axis, it requires intact pituitary function. Men with pituitary adenomas, prior pituitary surgery, or hyperprolactinemia should be evaluated carefully before starting.

Patient Selection: A Clinical Decision Guide

Men Who Should Start With Cypionate

• Primary hypogonadism confirmed by elevated LH and low testosterone.
• Men with Klinefelter syndrome or other genetic causes of testicular failure.
• Men who have completed their family and are not concerned with fertility.
• Men who failed a 12-week trial of enclomiphene without adequate testosterone response.
• Age above 65 with significant symptoms and clear biochemical hypogonadism (aligns with T-Trials enrollment criteria).

Men Who Should Consider Enclomiphene First

• Secondary hypogonadism (low or normal LH with low testosterone), which may include functional causes such as obesity, sleep apnea, or opioid use.
• Men actively attempting conception or planning to within 12 to 24 months.
• Younger men (ages 18 to 45) who wish to avoid long-term axis suppression.
• Men who prefer oral over injectable administration.
• Men with borderline-low testosterone (250 to 350 ng/dL) and mild symptoms where a trial of axis stimulation is warranted before committing to lifelong exogenous replacement.

When Neither Monotherapy Is Sufficient

Some clinicians combine low-dose testosterone cypionate (50 mg weekly) with hCG 500 IU three times weekly to maintain both testosterone levels and testicular function simultaneously. Enclomiphene is not typically combined with cypionate because the exogenous testosterone will suppress LH despite the SERM blockade at the hypothalamus, defeating the purpose of the enclomiphene.

Monitoring Timelines for Both Therapies

Consistent monitoring improves long-term safety and allows dose adjustments before problems accumulate.

Testosterone Cypionate monitoring schedule:

• Baseline: total testosterone (morning), hematocrit, PSA, lipid panel, estradiol.
• Week 6: total testosterone (trough, drawn immediately before injection), hematocrit.
• Month 3: total testosterone, hematocrit, PSA.
• Month 6 and annually: full panel including lipids and blood pressure.

Enclomiphene Citrate monitoring schedule:

• Baseline: total testosterone, LH, FSH, estradiol, semen analysis (if fertility is a goal).
• Week 6: total testosterone, LH, FSH, estradiol.
• Week 12: full repeat panel, semen analysis if applicable.
• Annually: testosterone, estradiol, PSA (in men above 40).

The Endocrine Society 2018 guideline recommends checking testosterone 3 to 6 months after starting therapy and annually thereafter, and obtaining a PSA and hematocrit at 3 to 6 months, 12 months, and then annually in men on testosterone therapy.

What the Evidence Does Not Yet Answer

The published trial record for enclomiphene caps out at 24 months of open-label data. No randomized controlled trial has followed men on enclomiphene for 5 or 10 years the way observational registries have tracked injectable testosterone users in Europe. This absence of long-term data means that questions about enclomiphene's effect on prostate health, bone mineral density, cardiovascular risk, and cognitive function over decades remain open. Cypionate, despite its longer commercial history, also lacks strong 10-year RCT data; most long-term safety data come from registries and observational cohorts with inherent selection bias.

Both drugs lack FDA approval for male hypogonadism-related fertility preservation, and insurance coverage for enclomiphene in men is inconsistent in the United States. Men should factor out-of-pocket costs into the durability calculation: a drug that works clinically but cannot be sustained financially is not durable in practice.